Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides

Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic

(2017) Ranjeet Prasad Dash et al.   Infectious Diseases

Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study

(2016) Peter Matzneller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society

(2016) Zhi-Kang Ye et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?

(2016) Junlan Chuan et al.   Frontiers in Pharmacology

Kidney Injury Associated with Telavancin Dosing Regimen in an Animal Model

(2015) Vincent H. Tam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects

(2015) Patrick J. Scoble et al.   CLINICAL DRUG INVESTIGATION

Oritavancin: A Long-Half-Life Lipoglycopeptide

(2015) Louis D. Saravolatz et al.   CLINICAL INFECTIOUS DISEASES

Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions

(2015) Eric Wenzler et al.   CLINICAL INFECTIOUS DISEASES

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method

(2015) Rodrigo E. Mendes et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment

(2015) Philip D. Worboys et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Vancomycin Tissue Pharmacokinetics in Patients with Lower-Limb Infections via In Vivo Microdialysis

(2015) Seth T. Housman et al.   JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION

Novel antibody–antibiotic conjugate eliminates intracellular S. aureus

(2015) Sophie M. Lehar et al.   NATURE

Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates

(2015) Shanshan Zhang et al.   PLoS One

Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing Methodologies

(2014) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae byIn VitroTime-Kill Experiments

(2014) T. Tängdén et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phagocytosis of Staphylococcus aureus by Human Neutrophils Prevents Macrophage Efferocytosis and Induces Programmed Necrosis

(2014) M. C. Greenlee-Wacker et al.   JOURNAL OF IMMUNOLOGY

The first report of the vanC1 gene in Enterococcus faecium isolated from a human clinical specimen

(2014) Mingyue Sun et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Comparative Activities of Telavancin Combined with Nafcillin, Imipenem, and Gentamicin against Staphylococcus aureus

(2013) Steven N. Leonard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia

(2013) Natasha E. Holmes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study

(2013) G. G. Zhanel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Presence of the Vancomycin Resistance Gene Cluster vanC1, vanXYc, and vanT in Enterococcus casseliflavus

(2013) Christina Hölzel et al.   Microbial Drug Resistance

Further Insights into the Mode of Action of the Lipoglycopeptide Telavancin through Global Gene Expression Studies

(2012) Yang Song et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

d-Ala-d-Ser VanN-Type Transferable Vancomycin Resistance in Enterococcus faecium

(2011) François Lebreton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin AUC24/MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus and Its Association with Attributable Mortality during Hospitalization

(2011) Jack Brown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mass Balance and Pharmacokinetics of [14C]Telavancin following Intravenous Administration to Healthy Male Volunteers

(2010) J.-P. Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Specificity of Induction of the vanA and vanB Operons in Vancomycin-Resistant Enterococci by Telavancin

(2010) C. M. Hill et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antistaphylococcal Activities of Telavancin Tested Alone and in Combination by Time-Kill Assay

(2010) G. Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Telavancin Studied in anIn VitroPharmacokinetic Model of Infection

(2010) Alasdair P. MacGowan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Ronald N. Jones   CLINICAL INFECTIOUS DISEASES

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

(2010) E. Rubinstein et al.   CLINICAL INFECTIOUS DISEASES

Effect of Telavancin on the Pharmacokinetics of the Cytochrome P450 3A Probe Substrate Midazolam: A Randomized, Double-Blind, Crossover Study in Healthy Subjects

(2010) Shekman L Wong et al.   PHARMACOTHERAPY

Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations

(2009) H. A. Nguyen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations

(2009) S. N. Leonard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lack of Pharmacokinetic Drug Interactions Following Concomitant Administration of Telavancin with Aztreonam or Piperacillin/Tazobactam in Healthy Participants

(2009) Shekman L. Wong et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment

(2009) Thomas Marbury et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Therapeutic Monitoring of Vancomycin in Adults

(2009) Michael J Rybak et al.   PHARMACOTHERAPY

Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States

(2008) D. C. Draghi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006

(2008) D. M. Sievert et al.   CLINICAL INFECTIOUS DISEASES

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

(2008) Martin E. Stryjewski et al.   CLINICAL INFECTIOUS DISEASES

Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis

(2008) S. Lemaire et al.   CLINICAL MICROBIOLOGY AND INFECTION

Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts)

(2008) M. Barcia-Macay et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY